Trial Profile
A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Niraparib (Primary)
- Indications Renal cell carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NICARAGUA
- 27 Dec 2023 Planned End Date changed from 1 Oct 2025 to 1 Apr 2024.
- 24 Oct 2023 Results of first interim analysis (n=44) assessing safety and efficacy in an expansion cohort of mUC presented at the 48th European Society for Medical Oncology Congress
- 11 Sep 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.